Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cevipabulin SCHEMBL4477222 | 1.00 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4042827 | 1.00 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4047501 | 0.99 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL5755942 | 0.99 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4488773 | 0.98 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| SCHEMBL4489209 | 0.97 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| SCHEMBL4483077 | 0.97 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| SCHEMBL4480772 | 0.97 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4216639 | 0.94 | ENPP1 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4211390 | 0.94 | ENPP1 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| US-7507739-B2 | 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH (US) | 2009-03-24 | — | — | US | disclosed |
| US-7396835-B2 | Process for the preparation of tubulin inhibitors | WYETH (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396835-B2 | Process for the preparation of tubulin inhibitors | WYETH (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1692137-B1 | PROCESS FOR THE PREPARATION OF TUBULIN INHIBITORS | WYETH CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1680425-B1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1680425-A1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | MBOAT4 4702/4885ALDH1A1 2537/4885POLB 1764/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | MBOAT4 2846/4885ALDH1A1 4197/4885POLB 1194/4885 |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | ABCC1, ABCB1, TUBB6 | MBOAT4 4305/4885ALDH1A1 1838/4885POLB 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.